Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1966 1
1967 1
1969 2
1970 1
1971 1
1972 5
1973 3
1974 3
1975 5
1976 6
1977 3
1978 5
1979 6
1980 3
1981 3
1982 9
1983 15
1984 13
1985 5
1986 16
1987 16
1988 19
1989 23
1990 27
1991 22
1992 32
1993 18
1994 28
1995 36
1996 56
1997 48
1998 52
1999 48
2000 70
2001 66
2002 83
2003 126
2004 153
2005 185
2006 210
2007 233
2008 296
2009 355
2010 405
2011 423
2012 458
2013 531
2014 600
2015 695
2016 710
2017 751
2018 896
2019 1066
2020 1286
2021 1460
2022 1786
2023 1833
2024 2216
2025 2575
2026 1354

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19,068 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean yong r[Author] (299 results)?
Take it slow.
Yang R. Yang R. Science. 2026 May 28;392(6801):994. doi: 10.1126/science.aei9226. Epub 2026 May 28. Science. 2026. PMID: 42207894 No abstract available.
Robust jumping-droplet condensation.
Du B, Cheng Y, Yang S, Liu Y, Jiang W, Lan Z, Yang R, Wen R, Ma X. Du B, et al. Among authors: yang r. Sci Bull (Beijing). 2026 May 15;71(9):2273-2282. doi: 10.1016/j.scib.2026.03.062. Epub 2026 Apr 1. Sci Bull (Beijing). 2026. PMID: 41966973
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China.
Lu S, Liu B, Luo Y, Sun L, Wu L, Han Z, Fan Y, Zhao Y, Li X, Xu H, Meng X, Liu Y, Zhang Z, Luo H, Ma X, Ma X, Shi Q, Zhang Z, Yang R, Wang P, Pan P, Ai X, Li J, Pu X, Wang Z, Fang J, He M, He Y, Guo S, Li J, Wang H, Zhang J, Chu Q, Liu X, Ying S, Wu H, Sun H, Ji Y, Zhou M, Cao C, Tang K, Li Z, Li D, Zhang Z, Li J, Zhou J, Yang H, Du Y, Yang H, Shi J, Chen H, Chen Z, Li W, Lu D, Hu M, Wang ZM, Li B, Xia MY. Lu S, et al. Among authors: yang r. Lancet. 2026 May 31:S0140-6736(26)00966-9. doi: 10.1016/S0140-6736(26)00966-9. Online ahead of print. Lancet. 2026. PMID: 42218899
A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.
Kuter DJ, Miura K, Patriarca A, Pulanić D, Radinoff A, Sapunarova K, Syrigou A, Yang R, Nguyen VA, Skelton E, Wang S, Yee DL, Patwari P; Mezagitamab ITP Phase 2 Trial Investigators. Kuter DJ, et al. Among authors: yang r. N Engl J Med. 2026 Apr 9;394(14):1388-1398. doi: 10.1056/NEJMoa2513120. N Engl J Med. 2026. PMID: 41950473 Clinical Trial.
Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors.
Mancuso ME, Chan AKC, Shanmukhaiah C, Lyu CJ, Zdziarska J, Mahlangu J, van Vulpen LFD, Chowdary P, Yang R, Lentz SR, Matsushita T, Clausen WHO, Rakhmatullin I, Oldenburg J; FRONTIER2 Investigators. Mancuso ME, et al. Among authors: yang r. N Engl J Med. 2026 Apr 30;394(17):1696-1709. doi: 10.1056/NEJMoa2517384. N Engl J Med. 2026. PMID: 42054679 Clinical Trial.
Targeting RBPMS selectively eliminates FOXO1-mediated stem cell signatures in mouse models of acute myeloid leukemia.
Liu P, Zhang S, Chen BY, Chang B, Jiang Y, Li X, Chen X, Li ZJ, Yang R, Wang X, Xu CH, Liu X, Liu N, Jia Y, Yu PC, Wang Y, Zong LJ, Hu CL, Hou H, Cao D, Li X, Deng CH, Ren YY, Zhao MY, Ma X, Cui R, Teng D, Chen M, Wang R, Jin J, Jiang SY, Yan X, Xue K, Zhang Q, Li J, Dai E, Shen S, Wang Z, Ye X, Zhang J, Liu Y, Cui W, Lu M, Zhao WL, Chang CK, He PC, Chen Z, Chen SJ, Zheng M, Sun XJ, Wang L. Liu P, et al. Among authors: yang r. Sci Transl Med. 2026 May 6;18(848):eadv8951. doi: 10.1126/scitranslmed.adv8951. Epub 2026 May 6. Sci Transl Med. 2026. PMID: 42090480
All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer.
Li CF, Wei Y, Lee HH, Chang WC, Xiong Y, Tang Y, Yang R, Yao J, Wang H, Wang X, Liu M, Park J, Fu J, Wang YN, Bai LY, Wang SC, Chou CW, Ling J, Chu YY, Xun Z, Liang H, Maitra A, Yao W, Yu D, Chiao PJ, Ying H, Hung MC. Li CF, et al. Among authors: yang r. Nat Commun. 2026 May 11. doi: 10.1038/s41467-026-72271-5. Online ahead of print. Nat Commun. 2026. PMID: 42115161 Free article.
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.
Cooper N, Broome CM, Miyakawa Y, McDonald V, Al-Samkari H, Khelif A, Cataland SR, Barcellini W, Yang R, Mei H, Matthijssens F, Hultberg A, Ciurlia G, Gandini D, Ayguasanosa J, De Beuf K, Pastouret S, Ghanima W, Rodeghiero F, Bussel JB; ADVANCE SC Investigator Trial Group. Cooper N, et al. Among authors: yang r. Am J Hematol. 2026 Jul;101(7):1494-1506. doi: 10.1002/ajh.70303. Epub 2026 Apr 6. Am J Hematol. 2026. PMID: 41943179 Clinical Trial.
19,068 results
You have reached the last available page of results. Please see the User Guide for more information.